ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Therapeutic Mycophenolic Acid Area-Under-Curve (MPA AUC) Levels Abolish Donor-Specific Antibody Formation in Established and De Novo Renal Transplant Patients

M. Waybill, S. Narins, R. Scott, H. Yang

PinnacleHealth Transplantation, Harrisburg, PA

Meeting: 2013 American Transplant Congress

Abstract number: B1000

Related Abstracts
  • Mycophenolic Acid Area-Under-Curve (MPA AUC) Levels Sufficient to Prevent Donor-Specific Antibody (DSA) Formation Are Not Associated With Higher Rates of CMV/EBV/BK Viral Infections
  • Prospective, 6 Month, Open Label, Conversion Study from Mycophenolate Mofetyl to Mycophenolic Acid Evaluating the Severity of Gastro-Intestinal Symptoms and Mycophenolic Acid Urinary Metabolite as a Surrogate Marker of Plasmatic Area Under the Curve

Background: Donor-specific antibody (DSA) formation is a key factor in development of antibody-mediated rejection and irreversible renal dysfunction. Prevention of DSA formation is critical, mandating therapeutic levels of all immunosuppressive agents, including MMF. Measurement of 2 hour MPA AUC levels provides precise and feasible assessment of the adequacy of individual MMF dosage. This was a retrospective study to determine if aggressive monitoring of MPA AUC levels and optimizing MMF therapy would affect formation of DSA.

Methods: Between October 2010 and November 2012, MPA AUC testing was performed on 264 DSA-negative renal transplant patients. Group 1 (clinical): 201 patients post-transplant>1 year (range 1-11 years) underwent MPA AUC testing for clinical indication (increased serum creatinine, increased immune cell function, side effects associated with MMF). Group 2 (preemptive): from May 2011-November 1, 2012, 63 patients post transplant < 1 year underwent preemptive AUC testing. Patients in both groups were assessed for MMF dosage, MPA AUC levels and DSA status.

Results: Group 1: at time of initial MPA AUC testing, 108 (54%) patients had subtherapeutic MPA AUC levels (<60). Dose adjustment was made in all patients who could tolerate higher doses and repeat MPA AUC testing was performed in 42 patients:

n=42 Initial testing Post-dosage change p value
MMF Dose (mg/d)±SEM 1192±90 1884±102 <0.0001
MPA AUC(mg h/L)±SEM 41.90±1.59 64.02±2.56 <0.0001

To date, 130 patients in Group 1 have undergone repeat testing for DSA (including 27/42 patients with initially subtherapeutic MPA AUC): all remain DSA negative.

Group 2: all patients underwent initial MPA AUC testing within 9 months of transplant. At initial testing, 13 (21%) patients had MPA AUC < 60, dose adjustment was made and repeat MPA AUC testing was performed:

n=13 Initial testing Post-dosage change p value
MMF Dose (mg/d)±SEM 1194±98 1731±196 <0.0001
MPA AUC(m h/ L)±SEM 45.97±4.02 68.15±2.39 <0.0001

To date, 36 patients in Group 2 have undergone repeat testing for DSA (including 9/13 patients with initially subtherapeutic MPA AUC): all remain DSA negative.

Conclusions: 1.There is an unexpectedly high incidence of inadequate MMF dosing, even within the first year of renal transplantation. 2. Aggressive and preemptive MPA AUC monitoring ensures therapeutic MMF dosing and results in low if not absent DSA formation in both established and de novo renal transplant patients.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Waybill M, Narins S, Scott R, Yang H. Therapeutic Mycophenolic Acid Area-Under-Curve (MPA AUC) Levels Abolish Donor-Specific Antibody Formation in Established and De Novo Renal Transplant Patients [abstract]. Am J Transplant. 2013; 13 (suppl 5). https://atcmeetingabstracts.com/abstract/therapeutic-mycophenolic-acid-area-under-curve-mpa-auc-levels-abolish-donor-specific-antibody-formation-in-established-and-de-novo-renal-transplant-patients/. Accessed January 19, 2021.

« Back to 2013 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.